Anthropic opens applications for $50,000 AI grants to accelerate rare disease drug discovery: How to apply

Anthropic is expanding its AI for Science programme with a dedicated funding initiative aimed at one of medicine's most difficult challenges: rare genetic diseases. The AI company is inviting researchers and early-stage biotechnology firms to apply for grants that provide up to $50,000 in Claude API credits over six months, hoping to encourage new approaches to disease discovery, diagnosis and drug development.

The latest call builds on Anthropic's broader AI for Science initiative, launched last year to support scientific research through access to its AI models. According to the company, previous recipients have used Claude for projects ranging from drug repurposing to quantum simulation. It now plans to organise future grants around specific research themes, beginning with rare diseases.

More from Tech

Although each rare disease affects a relatively small number of people, the combined burden is significant. More than 400 million people worldwide are estimated to live with one of over 7,000 rare diseases. Researchers often face fragmented patient data, limited understanding of disease mechanisms and lengthy drug development timelines, making progress particularly difficult.

How to apply

Applications for the new programme are open until August 2, 2026, at 11:59 PM PST. Anthropic has divided the initiative into two tracks.

The first is intended for academic and clinical researchers investigating the biological mechanisms behind rare diseases. Anthropic said successful applicants will work alongside organisations including the Monarch Initiative, an international consortium that develops tools and standards to improve rare disease diagnosis and research.

Among Monarch's projects is the Mondo Disease Ontology, which brings together disease classifications from multiple international databases, and the Monarch Knowledge Graph, designed to connect genetic and clinical information across species. Researchers in the programme will also have access to DisMech, a developing mechanistic disease classification resource that allows AI systems such as Claude to analyse case reports, genetic databases and other scientific resources to identify shared biological pathways between diseases.

Anthropic said it hopes participating researchers will contribute back to these open scientific resources while testing new hypotheses that could eventually support treatment development.

The second track targets biotech startups and translational researchers working to accelerate therapies for rare diseases. Rather than focusing on basic science, these projects are expected to explore how AI can streamline the lengthy processes involved in moving treatments towards clinical testing.

Examples include preparing regulatory submissions, analysing potential therapeutic strategies across different treatment modalities and identifying opportunities for broader clinical trial designs where multiple genetically related conditions could potentially be studied together.

How can AI help in research?

Anthropic argues that AI can address several longstanding bottlenecks in rare disease research, particularly where scientists must work with fragmented datasets spread across thousands of conditions. The company believes AI systems can help researchers synthesise scientific literature, identify patterns that may otherwise go unnoticed and organise information into formats that are easier to analyse.

For drug development, Anthropic said Claude could reduce the administrative burden associated with regulatory documentation, support early-stage analysis of potential drug targets and assist researchers in selecting the most promising therapeutic approaches. While manufacturing constraints and mandatory safety studies will continue to limit how quickly treatments reach patients, the company believes parts of the development process could be significantly shortened.

The programme also builds on collaborations with existing AI for Science partners. These include Every Cure, which is exploring drug repurposing opportunities using AI; the Centre for Population Genomics, which is developing AI-assisted systems to support genetic variant classification; and the Violet Research Institute, which uses Claude for tasks including bioinformatics analysis, regulatory documentation and navigating US Food and Drug Administration guidance.

Anthropic acknowledged that AI is not a complete solution. The company noted that limited or poor-quality data remains a major obstacle in many rare diseases, while challenges such as insurance approvals, access to specialist diagnostic services and healthcare infrastructure fall beyond the capabilities of AI alone.

Even so, the company said it hopes the new grant programme will encourage broader collaboration between researchers, patient organisations and biotech companies, while generating openly available scientific resources that could benefit the wider rare disease community. Outputs from the programme's first research track will be made publicly available through the Monarch Initiative, and Anthropic said future community activities, including rare disease hackathons, are also planned.